Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Symonds

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Gastroenterology|November 23, 2013
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infectionEdward J Gane, Catherine A Stedman, Robert H Hyland, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 27, 2006
Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosisLiu Yang, Che-Chang Chan, Oh-Sang Kwon, et al.
Antimicrobial Agents and Chemotherapy|February 13, 2001
Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy malesR E Polk, D F Brophy, D S Israel, et al.
The Journal of the Acoustical Society of America|May 19, 2005
Long range acoustic imaging of the continental shelf environment: the Acoustic Clutter Reconnaissance Experiment 2001Purnima Ratilal, Yisan Lai, Deanelle T Symonds, et al.
Annals of the New York Academy of Sciences|August 4, 2015
Development of sofosbuvir for the treatment of hepatitis C virus infectionEric Lawitz, Ira M Jacobson, David R Nelson, et al.
The Journal of the American Osteopathic Association|July 1, 1981
Electromyographic assessment of chronic low-back pain syndromeW H Hoyt, H H Hunt, M A De Pauw, et al.
Journal of Translational Medicine|July 13, 2007
Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infectionIan R White, Keyur Patel, William T Symonds, et al.
Journal of Hepatology|November 28, 2012
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trialMaribel Rodriguez-Torres, Eric Lawitz, Kris V Kowdley, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failedStanislas Pol, Mark S Sulkowski, Tarek Hassanein, et al.
Hepatology (Baltimore, Md.)|January 6, 2015
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantationXavier Forns, Michael Charlton, Jill Denning, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Gastroenterology|November 23, 2013
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infectionEdward J Gane, Catherine A Stedman, Robert H Hyland, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 27, 2006
Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosisLiu Yang, Che-Chang Chan, Oh-Sang Kwon, et al.
Antimicrobial Agents and Chemotherapy|February 13, 2001
Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy malesR E Polk, D F Brophy, D S Israel, et al.
The Journal of the Acoustical Society of America|May 19, 2005
Long range acoustic imaging of the continental shelf environment: the Acoustic Clutter Reconnaissance Experiment 2001Purnima Ratilal, Yisan Lai, Deanelle T Symonds, et al.
Annals of the New York Academy of Sciences|August 4, 2015
Development of sofosbuvir for the treatment of hepatitis C virus infectionEric Lawitz, Ira M Jacobson, David R Nelson, et al.
The Journal of the American Osteopathic Association|July 1, 1981
Electromyographic assessment of chronic low-back pain syndromeW H Hoyt, H H Hunt, M A De Pauw, et al.
Journal of Translational Medicine|July 13, 2007
Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infectionIan R White, Keyur Patel, William T Symonds, et al.
Journal of Hepatology|November 28, 2012
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trialMaribel Rodriguez-Torres, Eric Lawitz, Kris V Kowdley, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failedStanislas Pol, Mark S Sulkowski, Tarek Hassanein, et al.
Hepatology (Baltimore, Md.)|January 6, 2015
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantationXavier Forns, Michael Charlton, Jill Denning, et al.
Pageof 7